Helen Varsos

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen, Samir Parekh, Bianca Santomasso et al. · Blood Cancer Journal · 2022 · 270 citations · Full text

Medicine, Hematology, Oncology +17

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D. Cohen, María‐Victoria Mateos, Yaël C. Cohen et al. · Blood · 2022 · 201 citations · Full text

Medicine, Hematology, Oncology +17

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

David P. Steensma, Pierre Fenaux, Koen Van Eygen et al. · Journal of Clinical Oncology · 2020 · 125 citations · Full text

Medicine, Hematology, Pharmacology +13

Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy

Jeffrey Patton, Michael Kuzur, William H. Liggett et al. · The Oncologist · 2004 · 39 citations · Full text

Medicine, Hematology, Pharmacology +17

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Mounzer Agha, Adam D. Cohen, Deepu Madduri et al. · Journal of Clinical Oncology · 2021 · 31 citations

Medicine, Hematology, Oncology +15